首页> 外文期刊>海南医科大学学报(英文版) >Assessment of the efficacy and safety of bronchial artery perfusion chemotherapy combined with high-frequency hyperthermia for advanced non-small cell lung cancer
【24h】

Assessment of the efficacy and safety of bronchial artery perfusion chemotherapy combined with high-frequency hyperthermia for advanced non-small cell lung cancer

机译:支气管动脉灌注化疗联合高频热疗治疗晚期非小细胞肺癌的疗效和安全性评估

获取原文
获取原文并翻译 | 示例
           

摘要

Objective:To study the efficacy and safety of bronchial artery perfusion chemotherapy combined with high-frequency hyperthermia for advanced non-small cell lung cancer. Methods:Patients with advanced non-small cell lung cancer who were treated in Navy General Hospital between May 2014 and October 2016 were selected and randomly divided into two groups, the observation group received bronchial arterial infusion chemotherapy combined with high-frequency hyperthermia, and the control group received bronchial arterial infusion chemotherapy. Before and after treatment, the expression of tumor activity indexes and liver and kidney function indexes in serum as well as and proliferation and invasion genes in tumor lesions were detected respectively.Results: 5 d and 7 d after treatment, serum CEA, MIF, CYFRA21-1 and HE4 levels of both groups of patients were significantly lower than those before treatment and serum CEA, MIF, CYFRA21-1 and HE4 levels of observation group were significantly lower than those of control group; 7 d after treatment, MEF2D, c-myc, Survivin, Bcl-2, Vimentin, N-cadherin and Slug expression in tumor lesions of both groups of patients were significantly lower than those before treatment and MEF2D, c-myc, Survivin, Bcl-2, Vimentin, N-cadherin and Slug expression in tumor lesions of observation group were significantly lower than those of control group; serum Scr, BUN, ALT and AST levels were not significantly different between two groups of patients before and after treatment. Conclusion:Bronchial artery perfusion chemotherapy combined with high-frequency hyperthermia for advanced non-small cell lung cancer can significantly inhibit the tumor proliferation and invasion and is with ideal safety.
机译:目的:探讨支气管动脉灌注化疗联合高频热疗治疗晚期非小细胞肺癌的疗效和安全性。方法:选择2014年5月至2016年10月在海军总医院接受治疗的晚期非小细胞肺癌患者,随机分为两组,观察组接受支气管动脉灌注化疗联合高频热疗,对照组接受支气管动脉灌注化疗。治疗前后分别检测血清中肿瘤活性指标,肝肾功能指标的表达以及肿瘤病变中的增殖和侵袭基因。结果:治疗后5 d和7 d,血清CEA,MIF,CYFRA21两组患者的-1和HE4水平明显低于治疗前,观察组的血清CEA,MIF,CYFRA21-1和HE4水平明显低于对照组。治疗后7 d,两组患者肿瘤病变中的MEF2D,c-myc,Survivin,Bcl-2,波形蛋白,N-钙粘蛋白和Slug表达均显着低于治疗前,而MEF2D,c-myc,Survivin,Bcl -2,观察组肿瘤病变中波形蛋白,N-钙黏着蛋白和Slug的表达明显低于对照组。两组患者治疗前后的血清Scr,BUN,ALT和AST水平无明显差异。结论:支气管动脉灌注化疗联合高频热疗治疗晚期非小细胞肺癌可显着抑制肿瘤的增殖和侵袭,安全性理想。

著录项

  • 来源
    《海南医科大学学报(英文版)》 |2017年第11期|132-136|共5页
  • 作者

    Jia-Cheng Zhang; Wei Lu;

  • 作者单位

    Department of Interventional Medicine, Navy General Hospital, Beijing, 100048;

    Department of Interventional Medicine, Navy General Hospital, Beijing, 100048;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号